Sunday, May 3, 2026

The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’

NEW YORK - Friday, 01. May 2026


New Tickets, Exclusive Offers, and Special Anniversary Programs Kick off May 1


 


(BUSINESS WIRE)--The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future.


“The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust.


Anniversary Offerings and Experiences


To mark its 95th anniversary, the Empire State Building will debut new experiences and exclusive offerings, with additional announcements planned throughout the year.


Sundae Funday: Now available and extended through the rest of May due to popular demand, Ghirardelli Chocolate & Ice Cream Shop – located on the building’s ground floor – will sell the Kong Sundae on the building’s 86th Floor Observation Deck. The sundae features smooth vanilla ice cream crowned with Ghirardelli's signature handcrafted hot fudge, whipped cream, diced almonds, a cherry, and a Chocolatey Kong on top. The sweet treat is available exclusively on the observation deck before it arrives at the NYC shop at the base of the Empire State Building later this spring.

Sky High Celebrations: The first-ever ESB Birthday Party Package is now available and includes a guided visit through the Empire State Building Observation Deck’s galleries and the best views in New York City on the 86th Floor; a private party room with a Ghirardelli Chocolate & Ice Cream Shop sundae chef; artisanal snacks and drinks; and ESB-themed evites and party favors. For the ultimate experience, celebrants can include a visit to the premium 102nd Floor Observation Deck and can even add professional face painting and balloon twisting and a visit from the Empire State Building’s beloved mascot, Emma Pire. The package includes a party for 12 children and three adults, which can be expanded to accommodate up to 25 guests. ESB Birthday Party Packages must be booked at least 28 days in advance at esbnyc.com and are available for celebrations on Saturdays and Sundays from 10 a.m. to 3 p.m.

A Dazzling Milestone: ESB’s world-famous tower lights will shine in a dynamic, multi-color sparkle on May 1 to mark the milestone, visible across New York City and celebrated globally. Fans around the world can tune in live via EarthCam.

A Legacy That Leads


The Empire State Building is the world’s most recognizable landmark and stands as an international symbol of technology, imagination, and ambition since its construction in a mere 410 days. A reimagined visitor experience and ground-breaking retrofits serve as examples for other buildings and attractions across the globe.


Above the Rest: The Empire State Building was named the #1 Top Attraction in the U.S. in Tripadvisor’s 2026 Travelers’ Choice Awards: Best of the Best Things to Do. This prestigious honor, based on millions of traveler reviews and ratings, places the Empire State Building Observation Deck among the top one percent of attractions worldwide.

Reimagined Observation Deck Experience: A five-year, $165 million overhaul enhanced the visitor journey to the Empire State Building’s Observation Decks and introduced a new dedicated guest entrance and reservation office on 34th Street, an immersive museum with nine galleries, additional exhibits on the redesigned 80th Floor, a redesigned 102nd Floor Observation Deck with floor-to-ceiling windows, and brand new host uniforms which complete the redo.

Sustainability Leadership: The Empire State Building, the first building in New York State to achieve LEED v5 Platinum certification, sets the standard for high-performance building operations, with industry-leading energy efficiency and a clear path to net zero emissions by 2030. Through a landmark retrofit and continued innovation, the iconic tower has become one of the most energy-efficient buildings in the world, which demonstrates how historic landmarks can lead the future of sustainable real estate. To extend this leadership beyond its own portfolio, Empire State Realty Trust co-developed the open-source “Empire Building Playbook: An Owner’s Guide to Low Carbon Retrofits,” a first-of-its-kind resource that equips building owners worldwide with practical strategies to modernize operations, enhance efficiency, and achieve long-term sustainability goals with proven return on investment.

“For nearly a century, the Empire State Building has been a must-visit destination and one of the top things to do in NYC for travelers from around the world,” said Dan Rogoski, general manager of the Empire State Building Observation Deck. “From global leaders to pop culture icons, we have welcomed the world to the ‘World’s Most Famous Building’ – and today’s guests experience a completely reimagined Observation Deck that continues to set the standard for immersive attractions and tops the list of best observation decks in NYC.”


Additional anniversary moments, collaborations, and experiences will be announced throughout 2026. Reservations to the Empire State Building Observation Deck can be made online at esbnyc.com.


Images and b-roll of the Empire State Building’s archival footage, Empire State Building Observation Deck Experience, and signature lightings can be found here.


About the Empire State Building

The Empire State Building, the "World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observation Deck Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observation Deck with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observation Deck, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observation Deck Experience welcomes millions of visitors each year and is ranked the #1 Top Attraction in the United States in Tripadvisor's 2026 Travelers' Choice Awards: Best of the Best Things to Do, "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet's Ultimate Travel List. Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, Ghirardelli, and Starbucks. For more information and Empire State Building Observation Deck Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.


Source: Empire State Realty Trust, Inc.

Category: Empire State Building


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260430693323/en/



Permalink

https://www.aetoswire.com/en/news/1052026547177


Contacts

Media Contacts:

Jamie Heitner

212-400-3339

Jheitner@esrtreit.com

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend


 MIAMI - 

Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team.


 


(BUSINESS WIRE)--A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026.


Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage.


The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of two names born from the same region, Emilia-Romagna, Italy’s Food Valley, and united by shared values of excellence, passion, and family spirit.


For this special night Barilla and VCARB surprised team members by flying in their families to Miami, creating an unexpected dinner filled with hugs, laughter, connection and shared plates of pasta.


Making the evening even more special was a lineup of distinguished guests, including VCARB’s future champion Arvid Lindblad, who attended alongside his mother in reflection of the event’s family-first spirit, Formula 1® World Champion Nico Rosberg with his wife and Olympic champion Mikaela Shiffrin with fiancĂ©. Alongside them, guests included members of the wider Formula 1® ecosystem, from engineers and technical partners to broadcast crews and media, reflecting the many people who contribute to the sport throughout the season.


A chance for a reunion: something that isn’t a given when you’re traveling the world 24 weekends a year.


For one evening, that distance was bridged and at the heart of it all was pasta: Fusilloni and Racing Wheels, the new shape launched specifically for the race season in collaboration with Formula 1®, available on Walmart.com and rolling out across the United States later this year.


That feeling of togetherness, typical of the Italian family meals, will continue across the entire weekend, with families staying on to experience the race weekend, from Thursday’s dinner through to Sunday’s Grand Prix.


“Taking time to come together, even when schedules make it difficult, is at the heart of what we do,” said Melissa Tendick, President of Barilla Americas. “As we deepen our involvement with Formula 1®, including our new partnership with Visa Cash App Racing Bulls, we’re proud to create moments that bring people back to what matters most: connecting over a meal and feeling close to family and friends.” Arvid Lindblad, VCARB Driver said, “It was such a special evening getting to see everyone come together, where we all switched off and switched on our personal lives. Partnering with Barilla, a brand that shares our values and Italian roots, felt especially meaningful, highlighting the importance of connection and the people behind our success.”


And while engines keep racing in Miami, Barilla reminds us that family can be anywhere: at home, in the paddock, or around a shared table.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260430832316/en/



Permalink

https://www.aetoswire.com/en/news/2052026547366


Contacts

For further information, contact:

Barilla Group Media Relations

mediarelations@barilla.com

Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results

 LAS VEGAS - Friday, 01. May 2026 AETOSWire Print 



First Quarter Financial Highlights Include:

Remaining Performance Obligations (RPO) of $643.6 million, up 16.4% year over year

Adjusted Calculated Billings of $92.2 million, up 22.9% year over year

Adjusted Annualized Recurring Revenue (ARR) of $388.0 million, up 5.0% year over year


 


(BUSINESS WIRE)--Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2026.


“Our first quarter results reflect continued growth and accelerating momentum in our core Rimini Support™ business as organizations turn to the proven Rimini Smart Path™ to execute their global ERP and operational transaction processes faster, better and cheaper with more agility and speed to value – all within existing budgets,” said Seth Ravin, president and CEO, Rimini Street. “We help organizations avoid unnecessary, costly and risky ERP and other enterprise software upgrades, migrations and replatformings that often deliver low ROI and little competitive advantage. Instead, organizations can invest in the modernization of their existing systems by leveraging next generation Rimini Agentic AI ERP solutions that can be quickly and economically deployed over their current ERP and other enterprise software to deliver real competitive advantage.”


“We delivered strong first quarter 2026 results that built on second half 2025 momentum, reflecting continued, growing market demand for our differentiated, proven support and innovation solutions,” said Michael Perica, CFO, Rimini Street. “We continued to make additional strategic investments in new AI and innovation offerings to drive growth and further streamlined global operations to provide leverage with scale. Looking ahead, we remain focused on profitable growth, disciplined cost management and a strong balance sheet and cash position. Capital allocation actions in the quarter included a $10 million debt prepayment that reduced outstanding debt to $58.4 million and increased net cash to $73.8 million as of March 31, 2026.”


Select First Quarter 2026 Financial Results


Revenue was $105.5 million for the first quarter of 2026, an increase of 1.2% compared to $104.2 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, revenue increased by 5.2%.

U.S. revenue was $46.9 million for the first quarter of 2026, a decrease of 6.4% compared to $50.1 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, U.S. revenue decreased by 0.3%.

International revenue was $58.6 million for the first quarter of 2026, an increase of 8.3% compared to $54.1 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, international revenue increased by 9.9%.

Subscription revenue was $100.2 million, which accounted for 95.0% of total revenue for the first quarter of 2026, compared to subscription revenue of $99.0 million, which accounted for 95.0% of total revenue for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, subscription revenue was $97.0 million, or 94.9% of total revenue, for the first quarter of 2026 compared to $92.4 million, or 95.0% of total revenue, for the same period last year.

Annualized Recurring Revenue was $400.8 million for the first quarter of 2026, an increase of 1.2% compared to $396.2 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, Adjusted Annualized Recurring Revenue was $388.0 million for the first quarter of 2026, an increase of 5.0% compared to $369.6 million for the same period last year.

Active Clients as of March 31, 2026 were 3,130, an increase of 1.2% compared to 3,092 Active Clients as of March 31, 2025.

Revenue Retention Rate was 88% and 88% for the trailing 12 months ended March 31, 2026 and 2025, respectively.

Calculated Billings was $95.3 million for the first quarter of 2026, an increase of 19.9% compared to $79.4 million for the same period last year.

Adjusted Calculated Billings, which excludes Calculated Billings related to the support services for Oracle’s PeopleSoft software products, was $92.2 million for the first quarter of 2026, an increase of 22.9% compared to $75.0 million for the same period last year.

Remaining Performance Obligations (RPO) was $643.6 million as of March 31, 2026, an increase of 16.4% compared to $553.1 million as of March 31, 2025; excluding the support services for Oracle’s PeopleSoft software products, Adjusted RPO was $633.2 million as of March 31, 2026, an increase of 18.2% compared to $535.8 million as of March 31, 2025.

Gross margin was 59.0% for the first quarter of 2026 compared to 61.0% for the same period last year.

Operating income was $4.8 million for the first quarter of 2026 compared to $9.4 million for the same period last year.

Non-GAAP Operating Income was $7.9 million for the first quarter of 2026 compared to $14.5 million for the same period last year.

Net income was $1.4 million for the first quarter of 2026 compared to $3.4 million for the same period last year.

Non-GAAP Net Income was $4.0 million for the first quarter of 2026 compared to $9.5 million for the same period last year.

Adjusted EBITDA for the first quarter of 2026 was $8.9 million compared to $15.7 million for the same period last year.

Both the basic and diluted earnings per share attributable to common stockholders were $0.01 for the first quarter of 2026, compared to a basic and diluted earnings per share of $0.04 for the same period last year.

Cash and cash equivalents were $132.2 million at March 31, 2026 compared to $122.6 million at March 31, 2025.

Voluntary debt prepayment of $10.0 million during the first quarter, reducing the term loan outstanding to $58.4 million.

Select First Quarter 2026 Operating Results


Announced new and existing clients that expanded their agreements with Rimini Street, including the following:

LF, a leading South Korean lifestyle company, selected Rimini Support™ for SAP ECC 6.0 and Oracle Database to reduce maintenance costs, improve support quality and stability, and reinvest savings in AI-driven automation and digital transformation.

Cubic Corporation, a U.S. based global innovation technology partner for the defense and transportation industries, partnered with Rimini Street to support its strategy to modernize while maintaining SAP ECC as a stable core.

KleanNara, a leading South Korean manufacturer of paper and hygiene products, selected Rimini Support™ for its SAP ECC 6.0 and Oracle Database systems, freeing up funds and team focus for AI-driven innovation and growth.

Flexitech, a French manufacturer for the global automobile industry, selected Rimini Support™ for SAP to strengthen security, accelerate compliance readiness and free budget for R&D and modernization initiatives.

Lwart Environmental Solutions, a world leading Brazilian re-refinery and industrial sustainability organization, expanded its long-time partnership with Rimini Street by consolidating support for VMware and SAP support to regain control of its licensing and roadmap decisions, eliminating vendor-driven timelines and cost escalation.

Lotte Rental, South Korea’s top car rental company, selected Rimini Support™ for its SAP and Oracle systems, using the resulting savings to invest in AI, mobility services and cloud capabilities.

Resolved more than 6,800 support cases and delivered over 11,000 tax, legal, and regulatory updates across 23 countries, achieving an average client satisfaction score of 4.9 out of 5.0 (where 5.0 is rated excellent).

Received multiple industry Stevie® Awards for Best Use of AI in Customer Service, Front-Line Customer Service Team of the Year in the Technology Industry and Best Customer Satisfaction Strategy.

Business Outlook


The Company is providing second quarter 2026 revenue guidance to be in the range of $106 million to $108 million and reiterating the full year 2026 guidance provided at our Investor Day in December 2025 of revenue growth in the 4% to 6% range and Adjusted EBITDA margins in the 12.5% to 15.5% range (combined to achieve “Rule of 20”).


Webcast and Conference Call Information


Rimini Street will host a conference call and webcast to discuss the first quarter of 2026 results and offer commentary on full year 2026 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on April 30, 2026. A live webcast of the event will be available on Rimini Street’s Investor Relations site at Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference call by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event.


Company’s Use of Non-GAAP Financial Measures


This press release contains certain “non-GAAP financial measures.” Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by U.S. generally accepted accounting principles, or GAAP. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures determined in accordance with GAAP.


Reconciliations of the non-GAAP financial measures included in this press release and described below to their most directly comparable GAAP financial measures are provided in the financial tables included at the end of this press release. An explanation of these measures, why we believe they are meaningful and how they are calculated is also included under the heading “About Non-GAAP Financial Measures and Certain Key Metrics.”


About Rimini Street, Inc.


Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.


To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.


Forward-Looking Statements


Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for ERP software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; our wind down of support services for Oracle’s PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs, including those imposed by the United States government and the potential for retaliatory trade measures by affected countries; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States government and international governments and capture new contracts with governmental entities/agencies; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on April 30, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.


© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.



To provide investors and others with additional information regarding Rimini Street’s results, we have disclosed the following non-GAAP financial measures and certain key metrics. We have described below Active Clients, Annualized Recurring Revenue, Adjusted Annualized Recurring Revenue and Revenue Retention Rate, each of which is a key operational metric for our business. In addition, we have disclosed the following non-GAAP financial measures: non-GAAP operating income, non-GAAP net income, EBITDA, Adjusted EBITDA, Calculated Billings, Adjusted Calculated Billings, Remaining Performance Obligations and Adjusted Remaining Performance Obligations. In addition, we present certain financial metrics excluding our Oracle’s PeopleSoft software product offering to permit investors to see the operation of our continuing business, excluding reductions associated with the PeopleSoft wind down. Rimini Street has provided in the tables above a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. These non-GAAP financial measures are also described below.


The primary purpose of using non-GAAP measures is to provide supplemental information that management believes may prove useful to investors and to enable investors to evaluate our results in the same way management does. We also present the non-GAAP financial measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis, as well as comparing our results against the results of other companies, by excluding items that we do not believe are indicative of our core operating performance. Specifically, management uses these non-GAAP measures as measures of operating performance; to prepare our annual operating budget; to allocate resources to enhance the financial performance of our business; to evaluate the effectiveness of our business strategies; to provide consistency and comparability with past financial performance; to facilitate a comparison of our results with those of other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and in communications with our board of directors concerning our financial performance. Investors should be aware however, that not all companies define these non-GAAP measures consistently.


Active Client is a distinct entity that purchases our services to support a specific product, including a company, an educational or government institution, or a business unit of a company. For example, we count as two separate active clients when support for two different products is being provided to the same entity. We believe that our ability to expand our active clients is an indicator of the growth of our business, the success of our sales and marketing activities, and the value that our services bring to our clients.


Annualized Recurring Revenue is the amount of subscription revenue recognized during a fiscal quarter and multiplied by four. This gives us an indication of the revenue that can be earned in the following 12-month period from our existing client base, assuming no cancellations or price changes occur during that period. Subscription revenue excludes any non-recurring revenue, which has been insignificant to date.


Adjusted Annualized Recurring Revenue is annualized recurring revenue adjusted to exclude subscription revenue associated with services for Oracle’s PeopleSoft software products recognized during a fiscal quarter and multiplied by four.


Revenue Retention Rate is the actual subscription revenue (dollar-based) recognized over a 12-month period from customers that were clients on the day prior to the start of such 12-month period, divided by our Annualized Recurring Revenue as of the day prior to the start of the 12-month period.


Non-GAAP Operating Income is operating income adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs. The exclusions are discussed in further detail below.


Non-GAAP Income Taxes is the income tax effect adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs from income before income taxes.


Non-GAAP Net Income is net income adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs after taxes. These exclusions are discussed in further detail below.


Specifically, management excludes the following items from its non-GAAP financial measures, as applicable, for the periods presented:


Litigation Costs and Related Recoveries, Net: Litigation costs and the associated litigation settlement, insurance and appeal recoveries relate to outside costs of litigation activities. These costs and recoveries reflect the litigation we are involved with, and do not relate to the day-to-day operations or our core business of serving our clients.


Stock-Based Compensation Expense: Our compensation strategy includes the use of stock-based compensation to attract and retain employees. This strategy is principally aimed at aligning employee interests with those of our stockholders and to achieve long-term employee retention. As a result, stock-based compensation expense varies for reasons that are generally unrelated to operational decisions in any particular period.


Reorganization Costs: The costs consist primarily of severance costs associated with the Company's reorganization plan.


EBITDA is net income adjusted to exclude: interest expense, income taxes, and depreciation and amortization expense.


Adjusted EBITDA is EBITDA adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs, as discussed above. In addition, it is also adjusted by unrealized foreign exchange (gains) or losses.


Calculated Billings represents the change in deferred revenue for the current period plus revenue for the current period.


Adjusted Calculated Billings is calculated billings adjusted to exclude the calculated billings associated with services for Oracle’s PeopleSoft software products.


Remaining Performance Obligations represent all future non-cancellable revenue under contract that has not yet been recognized as revenue, and includes deferred revenue and unbilled amounts.


Adjusted Remaining Performance Obligations is the Company's remaining performance obligations adjusted to exclude the remaining performance obligations for services for Oracle’s PeopleSoft software products.


Rule of 20 is achieved when the revenue growth percentage and adjusted EBITDA percentage of revenue equal 20% when added together.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260430598629/en/



Permalink

https://www.aetoswire.com/en/news/1052026547155


Contacts

Investor Relations Contact

Dean Pohl

Rimini Street, Inc.

+1 925 523-7636

dpohl@riministreet.com


Media Relations Contact

Janet Ravin

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com


Saturday, May 2, 2026

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

DARMSTADT, Germany - Thursday, 30. April 2026 


    Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden
    Enpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards
    ELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity

 

(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations.

“People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.”

Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammation.1 By targeting these upstream drivers, enpatoran has the potential to impact disease activity and address a key aspect of the lupus mechanism that remains difficult to manage with current treatment approaches, while preserving the body’s broader immune function.1

“The ELOWEN program builds on Phase 2 findings, where enpatoran demonstrated clinically meaningful improvements in patients with active cutaneous manifestations, regardless of their underlying lupus diagnosis,” said Professor Eric Morand, principal investigator. “These studies are designed to further explore how targeting shared inflammatory pathways may benefit patients across the lupus spectrum.”

Lupus is a chronic autoimmune disease that can affect multiple organ systems, including the skin, joints, kidneys and central nervous system.2 Up to 85% of patients experience skin manifestations, which are among the most visible signs of disease and may reflect underlying immune-driven inflammation.1

Skin manifestations can be life-altering and sometimes are irreversible on their own.3,4 They can present as inflamed, photosensitive lesions on the face, scalp and other areas, and may lead to scarring or pigment changes.5 Despite their prevalence and the fact that skin manifestations are the first sign of disease in nearly one third (29%) of cases,1 many patients still do not achieve adequate disease control.6

“Skin symptoms impose a profound and multilayered burden that lingers long after flares subside. The lesions are visible, disfiguring and often painful, and the psychological weight can be equally debilitating, breeding a loss of identity that standard clinical assessments often fail to capture,” said Dr. Joy Buie, PhD, VP of Research at the Lupus Foundation of America. “These consequences erode participation in work, social life, and intimate relationships as self-consciousness and deliberate avoidance quietly reshape how patients navigate the world around them. It is vital we recognize skin manifestations as a visible and clinically actionable signal of underlying systemic disease "

ELOWEN-1 and ELOWEN-2 are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. The ELOWEN studies will be conducted in 266 sites in 26 countries. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.

About Enpatoran

Enpatoran is an investigational, oral, selective inhibitor of toll-like receptors 7 and 8 (TLR7/8), which play a key role in immune pathways involved in lupus. Enpatoran has the potential to be the first targeted therapy for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards of care for patients with CLE and SLE.

Enpatoran is currently under clinical investigation and has not been approved for any use anywhere in the world.

About the Phase 3 ELOWEN Program

ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218) are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. The ELOWEN studies will be conducted in 266 sites in 26 countries. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.

About Lupus Erythematosus

Lupus erythematosus is a chronic autoimmune disease characterized by inflammation that can affect multiple organs and systems in the body. The disease is heterogeneous, with symptoms ranging from mild to life-threatening, and often follows a relapsing-remitting course.

Cutaneous manifestations are common (72-85%) of patients and can occur alongside or independently of systemic involvement. Beyond their physical presentation, they are associated with increased disease burden, including scarring, psychological impact and reduced quality of life.

Lupus disproportionately affects women and people of color, and many patients continue to experience unmet medical needs due to insufficient disease control or treatment-related side effects.

Merck in Neurology and Immunology

Merck has a long-standing legacy in neurology and immunology. The company’s current neurology portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including lupus and generalized myasthenia gravis (gMG).

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

1 Childs B and Merola JF. From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists. J Clin Aesthet Dermatol. 2025;18(10):40–47.

2 Lupus Research Alliance. What Is Lupus? Available at: https://www.lupusresearch.org/about-lupus/what-is-lupus/. Last accessed: April 2026.

3 Klein R, Moghadam-Kia S, Taylor L, et al. Quality of Life in Cutaneous Lupus Erythematosus. J Am Acad Dermatol. 2011 Mar 12;64(5):849–858.

4 Chambers S, On A, Yang X, et al. Dyspigmentation and scarring in cutaneous lupus erythematosus. Lupus Sci Med. 2025;12(2).

5 Lupus Foundation of America. What is lupus? Available at: https://www.lupus.org/resources/what-is-lupus. Last accessed: April 2026.

6 Kandane-Rathnayake, Louthrenoo W, Hoi A, et al. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Res Ther. 2022;24:70.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430733656/en/

Permalink
https://www.aetoswire.com/en/news/54525685

Contacts
 

Media Relations
flavia.felix@emdserono.com
Phone: +1 781 427 1892

Friday, May 1, 2026

Estithmar Holding : bond spectaculaire de 97 % du bénéfice net au T1 2026, à 333 millions de riyals qataris

 

Estithmar Holding Q.P.S.C. a annoncĂ© ses rĂ©sultats financiers pour le premier trimestre 2026, faisant Ă©tat d’un bĂ©nĂ©fice net de 333 millions de riyals qataris, soit une augmentation significative de 97 % par rapport Ă  la mĂŞme pĂ©riode de l’annĂ©e prĂ©cĂ©dente. Ces rĂ©sultats soulignent la soliditĂ© du modèle opĂ©rationnel de la sociĂ©tĂ©, ainsi que l’exĂ©cution rĂ©ussie de sa stratĂ©gie d’expansion.

 

La sociĂ©tĂ© a enregistrĂ© des revenus de 1,455 milliard de riyals qataris, contre 1,309 milliard de riyals qataris au premier trimestre 2025. Le bĂ©nĂ©fice brut a atteint 561 millions de riyals qataris, contre 416 millions de riyals qataris, soit une progression annuelle de 35 %. L’EBITDA a augmentĂ© de 73 % pour atteindre 473 millions de riyals qataris, tandis que le bĂ©nĂ©fice par action a progressĂ© de 90 % pour s’Ă©tablir Ă  0,089 riyals qataris.

 

Ces rĂ©sultats reflètent une croissance globale Ă  travers l’ensemble des principaux indicateurs financiers, soutenue par une vision d’investissement claire et la capacitĂ© de Estithmar Holding Q.P.S.C. Ă  concilier expansion gĂ©ographique, diversification du portefeuille et efficacitĂ© opĂ©rationnelle. Les investissements internationaux annoncĂ©s au cours des pĂ©riodes prĂ©cĂ©dentes ont commencĂ© Ă  produire un impact tangible, contribuant Ă  la croissance des revenus, Ă  l’amĂ©lioration de la rentabilitĂ© et Ă  l’expansion de la base d’actifs.

 

La forte croissance du bĂ©nĂ©fice net est attribuĂ©e Ă  l’approche rigoureuse de la SociĂ©tĂ© en matière d’efficacitĂ© opĂ©rationnelle et de crĂ©ation de valeur, ainsi qu’Ă  une gestion prudente du capital et Ă  des pratiques efficaces de gestion des risques. Parallèlement, les initiatives de transformation numĂ©rique, notamment dans les domaines de l’automatisation et de l’intelligence artificielle, ont jouĂ© un rĂ´le clĂ© dans l’amĂ©lioration de la productivitĂ©, le renforcement de la gouvernance et l’optimisation des coĂ»ts.

 

Les rĂ©sultats mettent Ă©galement en Ă©vidence la contribution Ă©quilibrĂ©e des diffĂ©rents pĂ´les d’activitĂ© de la SociĂ©tĂ© — santĂ©, services, tourisme et dĂ©veloppement immobilier, ainsi qu’industries et contracting spĂ©cialisĂ© — illustrant la rĂ©ussite de chaque pĂ´le dans la mise en Ĺ“uvre de sa propre stratĂ©gie de croissance au sein d’un cadre stratĂ©gique intĂ©grĂ©.

 

Commentant ces résultats, Juan Leon, PDG de Estithmar Holding Q.P.S.C., a déclaré :

« Les rĂ©sultats du premier trimestre illustrent la soliditĂ© de notre modèle d’affaires et notre capacitĂ© Ă  gĂ©nĂ©rer simultanĂ©ment une croissance Ă  la fois accĂ©lĂ©rĂ©e et durable. Plus que de simples rĂ©sultats record, cette performance tĂ©moigne de la qualitĂ© de nos dĂ©cisions d’investissement et de l’exĂ©cution rigoureuse de notre stratĂ©gie Ă  travers les marchĂ©s et les secteurs. L’Ă©quilibre entre la croissance des revenus et l’amĂ©lioration de la rentabilitĂ©, soutenu par de solides performances opĂ©rationnelles et des flux de trĂ©sorerie sains, met en Ă©vidence notre efficacitĂ©, ainsi que notre capacitĂ© Ă  transformer l’expansion en valeur tangible et durable pour les actionnaires ».

 

Pour en savoir plus, consultez le communiqué de presse dans son intégralité.

 

La seule version du communiquĂ© qui fasse foi est celle du communiquĂ© dans sa langue d’origine. La traduction devra toujours ĂŞtre confrontĂ©e au texte source, qui fera jurisprudence.



Contacts

Experian Announces Agent Trust to Power Trusted AI Driven Commerce

 First-of-its-kind human-to-agent binding service for secure AI-driven commerce, developed with a growing ecosystem of agentic commerce collaborators, including Visa, Cloudflare and Skyfire


(BUSINESS WIRE) -- Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions.


As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions.


Experian Agent Trust addresses this challenge through a new “Know Your Agent” (KYA) framework, extending identity verification into the age of AI. The framework ensures that agent-initiated transactions are grounded in verified consumer identity.


“Agentic commerce will not scale without trust,” said Kathleen Peters, Chief Innovation Officer at Experian. “What’s required is verifying the agent, the human behind it, and their intent to purchase. This is a natural extension of Experian’s verification role in the ecosystem. We already help define trust in financial transactions; now we’re bringing that same leadership to agentic commerce.”


Experian Agent Trust is being developed within a growing ecosystem of collaborative agentic commerce contributors, including Visa, Cloudflare, and Skyfire, who are leading the development of secure and scalable AI-driven commerce across payments, networks, and digital interactions.


Trust Stack for Agentic Commerce


Within this ecosystem, Experian’s identity capabilities is designed to complement Visa Intelligent Commerce and Trusted Agent Protocol to support a layered framework for trust and secure agentic payments.


Experian Human to Agent Binding connects verified consumers, devices and AI agents, issuing a real time trust token that validates identity, and transaction risk.


Trusted Agent Protocol allows merchants to identify and verify AI agents through Visa’s trusted network to help confirm an agent’s legitimacy and authorization to act on behalf of a consumer.


Cloudflare enforces this trust layer at the network edge, where it already powers and protects approximately 20% of the world's internet traffic, and operates the next-generation AI stack to build, secure, and scale agents.


Visa Intelligent Commerce enables secure AI commerce transactions, using network tokenization.


Skyfire offers an open, standardized way to package and exchange agent-related information across platforms, enabling interoperability and complementing existing identity and payment systems.


“Visa has spent decades earning trust across global commerce, which matters even more as AI becomes part of how transactions happen,” said Rubail Birwadker, SVP, Head of Growth Products and Partnerships at Visa. “As the ecosystem evolves and approaches like Experian’s human-to-agent identity binding capabilities emerge, Visa Intelligent Commerce and Trusted Agent Protocol are designed to provide the secure foundation for agentic commerce experiences at global scale.”


"The rise of AI agents represents one of the most significant shifts in the history of digital commerce, but it can only succeed if the underlying infrastructure is rooted in trust,” said Stephanie Cohen, Chief Strategy Officer at Cloudflare. “Cloudflare is the best place to build and secure agents. By combining our network footprint with Experian's identity expertise, we're giving any business the tools to participate in agentic commerce with confidence."


“Agentic commerce only works if merchants can confidently understand who they are transacting with, and if agents can pay as reliably as people do,” said Amir Sarhangi, CEO and co-founder of Skyfire. “Through our collaboration with Experian’s Agent Trust ecosystem and our work on the Know Your Agent (KYAPay) protocol, we’re helping enable a seamless, interoperable trust layer that brings together identity and payments to unlock the full potential of autonomous transactions.”


A consumer might ask their AI agent to find the best noise-cancelling headset for an upcoming trip. The agent can evaluate products based on the consumer’s preferences and make a recommendation, for example a Bose headphone, and prepare the transaction for approval. Once the consumer authorizes the purchase, Human to Agent Binding helps confirm that the agent is acting on behalf of a verified individual.


Experian Agent Trust is designed to work with existing payment systems and frameworks, like Trusted Agent Protocol. At the center of the framework is Human-to-Agent Binding, which creates a secure, persistent link between verified individuals, their devices, and the AI agents. This enables a continuous, auditable history between who the user is, and how the agent behaves over time.


Experian issues an Agent Trust Token that validates identity, and transaction fraud risk in real-time. Together with the Experian Agent Registry, the system maintains dynamic trust scoring for AI agents based on behavior and other risk signals.


Built for an Open Ecosystem


Experian Agent Trust services are platform-agnostic and built to scale with the evolving agent ecosystem. By establishing a trusted connection between humans and AI agents, Experian is helping define the foundation for secure, scalable agentic commerce. These capabilities extend Experian’s leadership in identity verification and fraud prevention, where its solutions help clients avoid an estimated $15–19 billion in fraud losses annually.


To learn more, visit Experian’s blog: https://www.experian.com/blogs/news/2026/04/30/experian-agent-trust/


About Experian


Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.


We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.


We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 33 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.


Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260430719198/en/



Permalink

https://www.aetoswire.com/en/news/3004202654685


Contacts

Michael Troncale

Experian Public Relations

+1 714 830 5462

michael.troncale@experian.com


Annie Russell

Experian Public Relations

+1 949 683 5243

annie.russell@experian.com

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership


 BAAR, Switzerland -

Milestones advance clinical progress and path to commercialization


(BUSINESS WIRE) -- CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership.


Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monitoring Board) triggered the possibility for Phase 2 to begin in a larger wave of clinical trial sites in both the US and Europe.


The first patients in the MOCA II Phase II study were enrolled by Professor Marco Valgimigli at Cardiocentro Ticino Institute in Lugano, Switzerland. “I am excited to see the next generation of the CorFlow technology and advancement of the clinical program where the international pivotal study is now underway, for which the interventional cardiology community will eagerly await the results. Once the technology is readily available, it can help drive decision-making in the cath lab to improve our management of STEMI patients. Fast, accurate diagnosis of MVO is the key step we need to build from.”


CorFlow also announced that its parallel flagship clinical trial is now approved and can start enrolling patients. The novel randomized REVITALISE trial is now set to begin enrolment across UK, with France, Netherlands, and Spain following in the coming weeks. REVITALISE is intended to prospectively test the effectiveness of the proprietary CorFlow Continuous Flow Infusion System (CoFI System) to deliver therapeutic agents in treating MVO in patients undergoing primary angioplasty for acute myocardial infarction with ST segment elevation MI (STEMI). The trial intends to enroll at least 250 patients with early results expected in 2027 and data read-outs expected through 2028. The adaptive platform approach was selected due to its ability to add subsequent arms to the trial, testing the effectiveness of additional drug candidates delivered through the CorFlow system. Additional countries and research centers are also under evaluation.


Paul Mead, CEO of CorFlow, commented “With the momentum for our expanded clinical program and high interest from KOLs, we are now fortunate to be partnering with many of the top research institutions and physicians in the US and Europe to help bring the technology forward. Between both studies, we will have close to 50 top-tier hospitals engaged, each with a team motivated to see these studies succeed. Interventional cardiology, specifically in the coronary space, is at an exciting time once again with growth drivers and new options for patients. Our technology and clinical studies aim to build on that with a major step forward towards truly complete revascularization, including superior diagnosis and treatment options.”


Alongside the clinical program news, CorFlow has announced that Dr. Rick Kuntz has joined the CorFlow Board of Directors as an Observer and senior scientific advisor. Dr. Kuntz, a renowned interventional cardiologist, was a founder and Chief Scientific Officer of the Harvard Clinical Research Institute and later served at Medtronic as Chief Medical and Scientific Officer, where he oversaw medical affairs, health policy and reimbursement, clinical research activities, and corporate technology for the respected medical device leader. His experience includes guiding clinical programs for numerous technologies through market clearance and subsequent post market research for over 30 years.


CorFlow also announced the appointment of Dr. Pedro Eerdmans as Vice President Clinical. Pedro brings decades of experience from both industry, clinical research organizations, and notified bodies over his career, touching multiple medical fields. Notably, Dr. Eerdmans has helped scale medtech startups for clinical study execution, as well as spent time at larger medical companies such as Biosensors International where he served as VP Medical Affairs overseeing multiple coronary artery stent studies.


Chris O’Connell, the Chairman of the Board of CorFlow, commented, “We are thrilled with the clinical milestones that CorFlow continues to achieve, and equally excited by the added experience of our new team members. I personally had the chance to work with Dr. Kuntz at Medtronic for many years and cannot think of a better addition for CorFlow to help guide our strategic, scientific and regulatory path forward for this breakthrough technology. Our foundation will always be in medical science that puts the patient first, aiming for a new standard of care – which is possible thanks to this strengthened team and the path the company is now on with these landmark studies.”


About CorFlow Therapeutics: Founded and headquartered in Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced first announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow, starting with cardiac applications for heart attack patients. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to research applications for the unique patented technology with pharmaceutical options and new use cases.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260430413675/en/



Permalink

https://aetoswire.com/en/news/3004202654677


Contacts

Media and Scientific Contact

CorFlow Therapeutics AG

hello@corflow.ch